Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Liver Diseases

Free Subscription 15.10.2018 1 AJR Am J Roentgenol 1 Am J Gastroenterol 4 Anticancer Res 3 Biochem Biophys Res Commun 4 BMC Gastroenterol 1 Dig Dis Sci 1 Eur Radiol 2 Gastroenterology 22 Hepatology 1 Int J Cancer 1 J Gastroenterol 1 J Gastroenterol Hepatol 8 J Hepatol 1 N Engl J Med 1 Oncogene 1 Proc Natl Acad Sci U S A 1 Radiology 1 Transplantation

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. LAWRENCE EM, Pooler BD, Pickhardt PJ
   Opportunistic Screening for Hereditary Hemochromatosis With Unenhanced CT: Determination of an Optimal Liver Attenuation Threshold.
   AJR Am J Roentgenol. 2018 Oct 9:1-6. doi: 10.2214/AJR.18.19690.
   PubMed     Text format     Abstract available
   
   

   
   Am J Gastroenterol

2. AGARWAL PD, Lucey MR
   Genetic Variations Linked to Hepatocellular Carcinoma: Personalized Medicine Takes a Step Forward.
   Am J Gastroenterol. 2018 Oct 5. pii: 10.1038/s41395-018-0260.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

3. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
   Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
   Anticancer Res. 2018;38:6023-6026.
   PubMed     Text format     Abstract available
   
   
4. SUGIYAMA K, Narita Y, Mitani S, Honda K, et al
   Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
   Anticancer Res. 2018;38:5859-5866.
   PubMed     Text format     Abstract available
   
   
5. TAKAMORI S, Takada K, Toyokawa G, Azuma K, et al
   PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
   Anticancer Res. 2018;38:5897-5901.
   PubMed     Text format     Abstract available
   
   
6. COLLOT T, Fumet JD, Klopfenstein Q, Vincent J, et al
   Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
   Anticancer Res. 2018;38:5963-5968.
   PubMed     Text format     Abstract available
   
   

   
   Biochem Biophys Res Commun

7. GAO X, Cen L, Li F, Wen R, et al
   Oral administration of indole substituted dipyrido[2,3-d]pyrimidine derivative exhibits anti-tumor activity via inhibiting AKT and ERK1/2 on hepatocellular carcinoma.
   Biochem Biophys Res Commun. 2018 Oct 4. pii: S0006-291X(18)32053.
   PubMed     Text format     Abstract available
   
   
8. JI DG, Guan LY, Luo X, Ma F, et al
   Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKalpha/NF-kappaB pathway.
   Biochem Biophys Res Commun. 2018;501:33-40.
   PubMed     Text format     Abstract available
   
   
9. WANG B, Zhou TY, Nie CH, Wan DL, et al
   Bigelovin, a sesquiterpene lactone, suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS generation in liver cancer.
   Biochem Biophys Res Commun. 2018;499:156-163.
   PubMed     Text format     Abstract available
   
   

   
   BMC Gastroenterol

10. YUAN X, Chen J, Cheng Q, Zhao Y, et al
    Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery.
    BMC Gastroenterol. 2018;18:147.
    PubMed     Text format     Abstract available
    
    
11. PARDHE BD, Shakya S, Bhetwal A, Mathias J, et al
    Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal.
    BMC Gastroenterol. 2018;18:109.
    PubMed     Text format     Abstract available
    
    
12. KUHN T, Nonnenmacher T, Sookthai D, Schubel R, et al
    Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults.
    BMC Gastroenterol. 2018;18:113.
    PubMed     Text format     Abstract available
    
    
13. XIE W, Wang Q, Gao Y, Pan CQ, et al
    Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report.
    BMC Gastroenterol. 2018;18:142.
    PubMed     Text format     Abstract available
    
    

    
    Dig Dis Sci

14. CHO SY, Kim S, Son MJ, Rou WS, et al
    Clinical Significance of the Thioredoxin System and Thioredoxin-Domain-Containing Protein Family in Hepatocellular Carcinoma.
    Dig Dis Sci. 2018 Oct 4. pii: 10.1007/s10620-018-5307.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

15. AMADORI M, Barone D, Scarpi E, Oboldi D, et al
    Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
    Eur Radiol. 2018;28:2969-2978.
    PubMed     Text format     Abstract available
    
    

    
    Gastroenterology

16. MEHAL WZ
    Acetyl-Coenzyme A carboxylase inhibition in Nonalcoholic Steatohepatitis: Delivering as Anticipated.
    Gastroenterology. 2018 Oct 8. pii: S0016-5085(18)35103.
    PubMed     Text format    
    
    
17. GRETEN TF, Lai CW, Li G, Staveley-O'Carroll KF, et al
    Targeted and Immune-based Therapies for Hepatocellular Carcinoma.
    Gastroenterology. 2018 Oct 1. pii: S0016-5085(18)35082.
    PubMed     Text format     Abstract available
    
    

    
    Hepatology

18. LIASKOU E, Hirschfield GM
    Genetic association studies and the risk factors for developing the 'immuno-bile-logic' disease PBC.
    Hepatology. 2017 Oct 24. doi: 10.1002/hep.29603.
    PubMed     Text format    
    
    
19. LIU R, Li X, Huang Z, Zhao D, et al
    CHOP-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29540.
    PubMed     Text format     Abstract available
    
    
20. ERICE O, Munoz-Garrido P, Vaquero J, Perugorria MJ, et al
    MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
    Hepatology. 2017 Sep 18. doi: 10.1002/hep.29533.
    PubMed     Text format     Abstract available
    
    
21. PFEIFFENBERGER J, Beinhardt S, Gotthardt DN, Haag N, et al
    Pregnancy in Wilson's disease: Management and outcome.
    Hepatology. 2018;67:1261-1269.
    PubMed     Text format     Abstract available
    
    
22. KO E, Seo HW, Jung ES, Ju S, et al
    PI3Kdelta is a new therapeutic target in hepatocellular carcinoma.
    Hepatology. 2018 Oct 9. doi: 10.1002/hep.30307.
    PubMed     Text format     Abstract available
    
    
23. PERUGORRIA MJ, Olaizola P, Banales JM
    Cholangiocyte-to-Hepatocyte Differentiation: a Context Dependent Process and an Opportunity for Regenerative Medicine.
    Hepatology. 2018 Oct 8. doi: 10.1002/hep.30305.
    PubMed     Text format     Abstract available
    
    
24. NARDELLI S, Gioia S, Ridola L, Farcomeni A, et al
    Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30304.
    PubMed     Text format     Abstract available
    
    
25. LAI SW
    Proton pump inhibitors use and risk of hepatocellular carcinoma.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30302.
    PubMed     Text format     Abstract available
    
    
26. 
    Hepatology Highlights.
    Hepatology. 2018;68:1213-1216.
    PubMed     Text format    
    
    
27. BLANER WS
    Hepatic Stellate Cells (HSCs) and Retinoids: Towards A Much More Defined Relationship.
    Hepatology. 2018 Oct 4. doi: 10.1002/hep.30293.
    PubMed     Text format     Abstract available
    
    
28. JANSEN PLM
    Hydrodynamics of bile flow Lessons from computational modelling.
    Hepatology. 2017 Oct 27. doi: 10.1002/hep.29618.
    PubMed     Text format    
    
    
29. STRAVITZ RT, Gottfried M, Durkalski V, Fontana RJ, et al
    Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
    Hepatology. 2018;67:1003-1013.
    PubMed     Text format     Abstract available
    
    
30. HUO TI, Hsu CY, Liu PH
    Magic mirror on the wall: Which is the best biomarker for hepatocellular carcinoma?
    Hepatology. 2018;67:2482-2483.
    PubMed     Text format    
    
    
31. DEAR JW
    New biomarkers for drug-induced liver injury.
    Hepatology. 2018;67:2480-2481.
    PubMed     Text format    
    
    
32. ZHANG C, Song F
    Knockout of ULK1/2 protects against acetaminophen-induced acute liver injury independent of autophagy?
    Hepatology. 2018;67:2476-2477.
    PubMed     Text format    
    
    
33. LAI S, Iwakiri Y
    Is miR-21 a potent target for liver fibrosis?
    Hepatology. 2018;67:2082-2084.
    PubMed     Text format    
    
    
34. BAJAJ JS, Hylemon PB
    Gut-Liver Axis Alterations in Alcoholic Liver Disease: Are Bile Acids the Answer?
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29760.
    PubMed     Text format    
    
    
35. BELLENTANI S, Bedogni G, Tiribelli C
    Two drinks per day does not take your fatty liver away.
    Hepatology. 2018;67:2072-2073.
    PubMed     Text format    
    
    
36. ZHAO Q, Tang X, Wu J
    The association between nonalcoholic fatty liver disease and metabolic comorbidities.
    Hepatology. 2018;67:2474.
    PubMed     Text format    
    
    
37. STARLINGER P, Pereyra D, Haegele S, Braeuer P, et al
    Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection.
    Hepatology. 2018;67:1516-1530.
    PubMed     Text format     Abstract available
    
    
38. WOO BAIDAL JA, Cheng ER, Rifas-Shiman SL, Oken E, et al
    Association of vitamin E intake at early childhood with alanine aminotransferase levels at mid-childhood.
    Hepatology. 2018;67:1339-1347.
    PubMed     Text format     Abstract available
    
    
39. ELLIS JL, Bove KE, Schuetz EG, Leino D, et al
    Zebrafish abcb11b mutant reveals novel strategies to restore bile excretion impaired by bile salt export pump deficiency.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29632.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

40. YANG J, Trepo E, Nahon P, Cao Q, et al
    PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31910.
    PubMed     Text format     Abstract available
    
    

    
    J Gastroenterol

41. PARK HE, Lee H, Choi SY, Kwak MS, et al
    Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter.
    J Gastroenterol. 2018 Oct 4. pii: 10.1007/s00535-018-1516.
    PubMed     Text format     Abstract available
    
    

    
    J Gastroenterol Hepatol

42. COOL J, Rosenblatt R, Kumar S, Lucero C, et al
    PORTAL VEIN THROMBOSIS PREVALENCE AND ASSOCIATED MORTALITY IN CIRRHOSIS IN A NATIONALLY REPRESENTATIVE INPATIENT COHORT.
    J Gastroenterol Hepatol. 2018 Oct 11. doi: 10.1111/jgh.14501.
    PubMed     Text format     Abstract available
    
    

    
    J Hepatol

43. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed     Text format    
    
    
44. SAGGI H, Maitra D, Jiang A, Zhang R, et al
    Loss of hepatocyte beta-Catenin protects mice from experimental porphyria-associated liver injury.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32442.
    PubMed     Text format     Abstract available
    
    
45. CHEN Y, Chen HN, Wang K, Zhang L, et al
    Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32441.
    PubMed     Text format     Abstract available
    
    
46. JAYAKUMAR S, Middleton MS, Lawitz EJ, Mantry PS, et al
    Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib.
    J Hepatol. 2018 Oct 3. pii: S0168-8278(18)32443.
    PubMed     Text format     Abstract available
    
    
47. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed     Text format    
    
    
48. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed     Text format    
    
    
49. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    
    
    
50. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed     Text format    
    
    

    
    N Engl J Med

51. MAEDA O, Ando Y
    Cabozantinib in Hepatocellular Carcinoma.
    N Engl J Med. 2018;379:1384.
    PubMed     Text format    
    
    

    
    Oncogene

52. DI RUOCCO F, Basso V, Rivoire M, Mehlen P, et al
    Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression.
    Oncogene. 2018;37:627-637.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

53. SONNTAG R, Giebeler N, Nevzorova YA, Bangen JM, et al
    Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.
    Proc Natl Acad Sci U S A. 2018;115:9282-9287.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

54. KHALAF MH, Sundaram V, AbdelRazek Mohammed MA, Shah R, et al
    A Predictive Model for Postembolization Syndrome after Transarterial Hepatic Chemoembolization of Hepatocellular Carcinoma.
    Radiology. 2018 Oct 9:180257. doi: 10.1148/radiol.2018180257.
    PubMed     Text format     Abstract available
    
    

    
    Transplantation

55. RATZIU V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G, et al
    Recommendations for management and treatment of nonalcoholic steatohepatitis.
    Transplantation. 2018 Oct 8. doi: 10.1097/TP.0000000000002483.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: